Details

Autor(en) / Beteiligte

• Stone, Gregg W
• Rizvi, Ali
• Newman, William
• Mastali, Kourosh
• Wang, John C
• Caputo, Ronald
• Doostzadeh, Julie
• Cao, Sherry
• Simonton, Charles A
• Sudhir, Krishnankutty
• Lansky, Alexandra J
• Cutlip, Donald E
• Kereiakes, Dean J

Titel

Everolimus-Eluting versus Paclitaxel-Eluting Stents in Coronary Artery Disease

Ist Teil von

• The New England journal of medicine, 2010-05, Vol.362 (18), p.1663-1674

Ort / Verlag

Waltham, MA: Massachusetts Medical Society

Erscheinungsjahr

2010

Quelle

MEDLINE

Beschreibungen/Notizen

• This clinical trial compared the effectiveness of an everolimus-eluting coronary stent with that of a paclitaxel-eluting stent in patients with coronary artery disease. Clinical outcomes at 1 year were superior with the everolimus-eluting stent in patients without diabetes, but not in patients with diabetes. These results are likely to influence clinical practice. This trial compared the effectiveness of an everolimus-eluting coronary stent with that of a paclitaxel-eluting stent in patients with coronary artery disease. Clinical outcomes at 1 year were superior with the everolimus-eluting stent in patients without diabetes, but not in patients with diabetes. Among patients undergoing percutaneous coronary intervention (PCI), the use of paclitaxel-eluting stents or sirolimus-eluting stents, as compared with use of bare-metal stents alone, reduces the rate of restenosis, as assessed clinically and angiographically. 1 , 2 Nevertheless, restenosis still occurs with drug-eluting stents, and the ongoing propensity for stent thrombosis necessitates the prolonged use of dual antiplatelet therapy. 1 – 5 Efforts have therefore focused on designing safer, more effective drug-eluting stents. An everolimus-eluting stent has been developed in which the drug is released from a thin (7.8-μm) fluorocopolymer coated onto a low-profile (81-μm strut thickness) cobalt–chromium stent. 6 Previously, the SPIRIT II and SPIRIT . . .